Lon­za of­floads spe­cial­ty in­gre­di­ents unit in $4.7B sale to Bain Cap­i­tal, Cin­ven in con­sol­i­da­tion around bio­phar­ma

With the bio­phar­ma CD­MO mar­ket on a years­long up­swing, gi­ant Lon­za has looked to re­work the game plan to keep its gold­en goose pro­duc­tive. Af­ter tin­ker­ing with its cap­sule of­fer­ings, the Swiss man­u­fac­tur­er will now of­fload an in­gre­di­ents unit that was once one of its busi­ness pil­lars.

Lon­za will sell its spe­cial­ty in­gre­di­ents busi­ness to Bain Cap­i­tal and UK pri­vate eq­ui­ty firm Cin­ven for $4.67 bil­lion as the con­tract man­u­fac­tur­er con­tin­ues to con­sol­i­date its busi­ness around bio­phar­ma work and cap­sules, the com­pa­ny said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.